BACKGROUND AND PURPOSE: Arachidonic acid that is released following cerebral ischemia can be metabolized to 20-hydroxyeicosatetraenoic acid (20-HETE). 20-HETE is a potent vasoconstrictor that may contribute to ischemic injury. This study examined the effects of blockading the synthesis of 20-HETE with TS-011 on infarct size after transient occlusion of the middle cerebral artery (MCAO) of rats and after thromboembolic stroke in monkeys. METHODS: Rats were treated with TS-011 or vehicle at various times after MCAO. Infarct size was measured by 2,3,5-triphenyltetrazolium chloride (TTC) staining and plasma levels of 20-HETE were determined by liquid chromatography mass spectrometry (LC/MS). The effect of TS-011 on infarct size was also studied in monkeys after introduction of a clot into the internal carotid artery. RESULTS: Plasma levels of 20-HETE increased after MCAO in rats. TS-011 (0.01 to 1.0 mg/kg per hour) reduced infarct volume by 40%. Chronic administration of TS-011 for 7 days reduced neurological deficits after MCAO in rats. TS-011 given in combination with tissue plasminogen activator also improved neurological outcome in the stroke model in monkeys. CONCLUSIONS: These results suggest that blockade of the formation of 20-HETE with TS-011 may be useful for the treatment of ischemic stroke.
BACKGROUND AND PURPOSE:Arachidonic acid that is released following cerebral ischemia can be metabolized to 20-hydroxyeicosatetraenoic acid (20-HETE). 20-HETE is a potent vasoconstrictor that may contribute to ischemic injury. This study examined the effects of blockading the synthesis of 20-HETE with TS-011 on infarct size after transient occlusion of the middle cerebral artery (MCAO) of rats and after thromboembolic stroke in monkeys. METHODS:Rats were treated with TS-011 or vehicle at various times after MCAO. Infarct size was measured by 2,3,5-triphenyltetrazolium chloride (TTC) staining and plasma levels of 20-HETE were determined by liquid chromatography mass spectrometry (LC/MS). The effect of TS-011 on infarct size was also studied in monkeys after introduction of a clot into the internal carotid artery. RESULTS: Plasma levels of 20-HETE increased after MCAO in rats. TS-011 (0.01 to 1.0 mg/kg per hour) reduced infarct volume by 40%. Chronic administration of TS-011 for 7 days reduced neurological deficits after MCAO in rats. TS-011 given in combination with tissue plasminogen activator also improved neurological outcome in the stroke model in monkeys. CONCLUSIONS: These results suggest that blockade of the formation of 20-HETE with TS-011 may be useful for the treatment of ischemic stroke.
Authors: Junchao Zhu; Bing Wang; Jeong-Hoo Lee; Jillian S Armstrong; Ewa Kulikowicz; Utpal S Bhalala; Lee J Martin; Raymond C Koehler; Zeng-Jin Yang Journal: Dev Neurosci Date: 2015-02-25 Impact factor: 2.984
Authors: Shiyu Shu; Zhi Zhang; Dawn Spicer; Ewa Kulikowicz; Ke Hu; Savalan Babapoor-Farrokhran; Sujatha Kannan; Raymond C Koehler; Courtney L Robertson Journal: Dev Neurosci Date: 2019-09-25 Impact factor: 2.984
Authors: Elizabeth A Crago; Bhavani P Thampatty; Paula R Sherwood; Chie-Wen J Kuo; Catherine Bender; Jeffrey Balzer; Michael Horowitz; Samuel M Poloyac Journal: Stroke Date: 2011-05-26 Impact factor: 7.914
Authors: Marija Renic; Suresh N Kumar; Debebe Gebremedhin; Matthew A Florence; Nashaat Z Gerges; John R Falck; David R Harder; Richard J Roman Journal: Am J Physiol Heart Circ Physiol Date: 2012-01-13 Impact factor: 4.733
Authors: Kathryn M Dunn; Marija Renic; Averia K Flasch; David R Harder; John Falck; Richard J Roman Journal: Am J Physiol Heart Circ Physiol Date: 2008-10-24 Impact factor: 4.733